{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:43:46Z","timestamp":1790401426594,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In vivo tau-PET tracer retention in the anterior temporal lobe of patients with semantic variant primary progressive aphasia (SV PPA) has consistently been reported. This is unexpected as the majority of these patients have frontotemporal lobar degeneration TDP (FTLD-TDP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted an in vitro [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV1451 autoradiography binding study in five cases with a clinical diagnosis of SV PPA constituting the range of pathologies (i.e., three FTLD-TDP, one Alzheimer\u2019s disease (AD), and one Pick\u2019s disease (PiD)). Binding was compared with two controls without neurodegeneration, two typical AD, one corticobasal syndrome with underlying AD, and one frontotemporal dementia behavioral variant with FTLD-TDP. The effect of blocking with the authentic reference material and with the MAO-B inhibitor deprenyl was assessed. Immunohistochemistry was performed on adjacent cryosections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Absence of specific [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV1451 binding was observed for all three SV PPA FTLD-TDP cases. The absence of binding in controls as well as the successful blocking with authentic AV1451 in cases with tauopathy demonstrated specificity of the [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV1451 signal for tau. The specific [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV1451 binding was highest in AD, followed by PiD. This binding colocalized with the respective tau lesions and could not be blocked by deprenyl. Similar pilot findings were obtained with [\n                      <jats:sup>18<\/jats:sup>\n                      F]THK5351.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In vitro autoradiography showed no [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV1451 binding in SV PPA due to FTLD-TDP, while specific binding was present in SV PPA due to AD and PiD. The discrepancy between in vitro and in vivo findings remains to be explained. The discordance is not related to [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV1451 idiosyncrasies as [\n                      <jats:sup>18<\/jats:sup>\n                      F]THK5351 findings were similar.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-019-04631-x","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T21:02:41Z","timestamp":1576616561000},"page":"1949-1960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-0568","authenticated-orcid":false,"given":"Jolien","family":"Schaeverbeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Celen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Cornelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Ronisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Serdons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar Rudolf","family":"Thal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"4631_CR1","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/115.6.1783","volume":"115","author":"JR Hodges","year":"1992","unstructured":"Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain. 1992;115:1783\u2013806.","journal-title":"Brain."},{"key":"4631_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1\u201310.","journal-title":"Neurology."},{"key":"4631_CR3","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.neurobiolaging.2008.02.005","volume":"30","author":"RR Davies","year":"2009","unstructured":"Davies RR, Halliday GM, Xuereb JH, Kril JJ, Hodges JR. The neural basis of semantic memory: evidence from semantic dementia. Neurobiol Aging. 2009;30:2043\u201352.","journal-title":"Neurobiol Aging"},{"key":"4631_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrneurol.2009.216","volume":"6","author":"M Grossman","year":"2010","unstructured":"Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol. 2010;6:88\u201397.","journal-title":"Nat Rev Neurol"},{"key":"4631_CR5","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/brain\/awu024","volume":"137","author":"M-M Mesulam","year":"2014","unstructured":"Mesulam M-M, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimer\u2019s and frontotemporal pathology in primary progressive aphasia. Brain. 2014;137:1176\u201392.","journal-title":"Brain."},{"key":"4631_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13195-016-0185-y","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R. Classification of the primary progressive aphasias: principles and review of progress since 2011. Alzheimers Res Ther. 2016;8:16.","journal-title":"Alzheimers Res Ther"},{"key":"4631_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457\u201368.","journal-title":"J Alzheimers Dis"},{"key":"4631_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","volume":"57","author":"R Harada","year":"2016","unstructured":"Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. [18F]-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208\u201314.","journal-title":"J Nucl Med"},{"key":"4631_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ana.25183","volume":"83","author":"KA Josephs","year":"2018","unstructured":"Josephs KA, Martin PR, Botha H, Schwarz CG, Duffy JR, Clark HM, et al. [18F]AV-1451 tau-PET and primary progressive aphasia. Ann Neurol. 2018;83:599\u2013611.","journal-title":"Ann Neurol"},{"key":"4631_CR10","doi-asserted-by":"crossref","unstructured":"Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A, et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2017:316\u2013409.","DOI":"10.1136\/jnnp-2017-316409"},{"key":"4631_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/jnnp-2017-316402","volume":"89","author":"WR Bevan-Jones","year":"2018","unstructured":"Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD, et al. [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89:1032\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4631_CR12","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1038\/s41598-019-42625-9","volume":"9","author":"R Smith","year":"2019","unstructured":"Smith R, Santillo AF, Wald\u00f6 ML, Strandberg O, Berron D, Vestberg S, et al. 18F-flortaucipir in TDP-43 associated frontotemporal dementia. Sci Rep. 2019;9:6082.","journal-title":"Sci Rep"},{"key":"4631_CR13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s00259-018-4075-3","volume":"45","author":"J Schaeverbeke","year":"2018","unstructured":"Schaeverbeke J, Evenepoel C, Declercq L, Gabel S, Meersmans K, Bruffaerts R, et al. Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants. Eur J Nucl Med Mol Imaging. 2018;45:2342\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4631_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neurobiolaging.2018.11.017","volume":"75","author":"H Cho","year":"2019","unstructured":"Cho H, Kim HJ, Choi JY, Ryu YH, Lee MS, Na DL, et al. 18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia. Neurobiol Aging. 2019;75:187\u201397.","journal-title":"Neurobiol Aging"},{"key":"4631_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/WAD.0000000000000216","volume":"32","author":"H Lee","year":"2017","unstructured":"Lee H, Seo S, Lee S-Y, Jeong HJ, Woo S-H, Lee K-M, et al. [18F]-THK5351 PET imaging in patients with semantic variant primary progressive aphasia. Alzheimer Dis Assoc Disord. 2017;32:62\u20139.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"4631_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12883-018-1115-3","volume":"18","author":"R Kobayashi","year":"2018","unstructured":"Kobayashi R, Hayashi H, Kawakatsu S, Ishiki A, Okamura N, Arai H, et al. [18F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review. BMC Neurol. 2018;18:109.","journal-title":"BMC Neurol"},{"key":"4631_CR17","first-page":"781","volume":"140","author":"L Passamonti","year":"2017","unstructured":"Passamonti L, Vazquez Rodriguez P, Hong YT, Allinson KSJ, Williamson D, Borchert RJ, et al. 18 F-AV-1451 positron emission tomography in Alzheimer\u2019s disease and progressive supranuclear palsy. Brain. 2017;140:781\u201391.","journal-title":"Brain."},{"key":"4631_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00401-016-1618-1","volume":"132","author":"KA Josephs","year":"2016","unstructured":"Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:931\u20133.","journal-title":"Acta Neuropathol"},{"key":"4631_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.24844","volume":"81","author":"M Marqui\u00e9","year":"2017","unstructured":"Marqui\u00e9 M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Ant\u00f3n-Fern\u00e1ndez A, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol. 2017;81:117\u201328.","journal-title":"Ann Neurol"},{"key":"4631_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.","journal-title":"Acta Neuropathol Commun"},{"key":"4631_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","volume":"11","author":"RM Tsai","year":"2019","unstructured":"Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;11:13.","journal-title":"Alzheimers Res Ther"},{"key":"4631_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marqui\u00e9","year":"2015","unstructured":"Marqui\u00e9 M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787\u2013800.","journal-title":"Ann Neurol"},{"key":"4631_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","volume":"12","author":"K Sander","year":"2016","unstructured":"Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12:1116\u201324.","journal-title":"Alzheimers Dement"},{"key":"4631_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mds.27271","volume":"33","author":"C Vermeiren","year":"2018","unstructured":"Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade J-P, Citron M, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33:273\u201381.","journal-title":"Mov Disord"},{"key":"4631_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces [18F]-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25.","journal-title":"Alzheimers Res Ther"},{"key":"4631_CR26","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/brain\/awh250","volume":"127","author":"M Broe","year":"2004","unstructured":"Broe M, Kril J, Halliday GM. Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain. 2004;127:2214\u201320.","journal-title":"Brain."},{"key":"4631_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.110.087031","volume":"53","author":"SF Carter","year":"2012","unstructured":"Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-Deuterium-L-Deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37\u201346.","journal-title":"J Nucl Med"},{"key":"4631_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement Elsevier Ltd. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"4631_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503.","journal-title":"Neurology."},{"key":"4631_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/09540261.2013.763341","volume":"25","author":"K Rascovsky","year":"2013","unstructured":"Rascovsky K, Grossman M. Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration. Int Rev Psychiatry. 2013;25:145\u201358.","journal-title":"Int Rev Psychiatry"},{"key":"4631_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"4631_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389\u2013404.","journal-title":"Acta Neuropathol"},{"key":"4631_CR33","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology."},{"key":"4631_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology. 1991;41:479\u201386.","journal-title":"Neurology."},{"key":"4631_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement NIH Public Access. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"4631_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","volume":"122","author":"IRA Mackenzie","year":"2011","unstructured":"Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111\u20133.","journal-title":"Acta Neuropathol"},{"key":"4631_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-017-1679-9","volume":"134","author":"EB Lee","year":"2017","unstructured":"Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65\u201378.","journal-title":"Acta Neuropathol"},{"key":"4631_CR38","doi-asserted-by":"crossref","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128.","DOI":"10.1007\/s00401-014-1349-0"},{"key":"4631_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1536012115624920","volume":"15","author":"L Declercq","year":"2016","unstructured":"Declercq L, Celen S, Lecina J, Ahamed M, Tousseyn T, Moechars D, et al. Comparison of new tau PET-tracer candidates with [18F]T808 and [18F]T807. Mol Imaging. 2016;15:1\u201315.","journal-title":"Mol Imaging"},{"key":"4631_CR40","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","volume":"54","author":"N Okamura","year":"2013","unstructured":"Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420\u20137.","journal-title":"J Nucl Med"},{"key":"4631_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"C-F Xia","year":"2013","unstructured":"Xia C-F, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimers Dement. 2013;9:666\u201376.","journal-title":"Alzheimers Dement"},{"key":"4631_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","volume":"62","author":"J Saura","year":"1994","unstructured":"Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15\u201330.","journal-title":"Neuroscience."},{"key":"4631_CR43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/jcbfm.2013.19","volume":"33","author":"J Tong","year":"2013","unstructured":"Tong J, Meyer JH, Furukawa Y, Boileau I, Chang L-J, Wilson AA, et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2013;33:863\u201371.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4631_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neuint.2010.10.013","volume":"58","author":"B Guly\u00e1s","year":"2011","unstructured":"Guly\u00e1s B, Pavlova E, K\u00e1sa P, Gulya K, Bakota L, V\u00e1rszegi S, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011;58:60\u20138.","journal-title":"Neurochem Int"},{"key":"4631_CR45","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-017-1740-8","volume":"134","author":"M Marqui\u00e9","year":"2017","unstructured":"Marqui\u00e9 M, Siao Tick Chong M, Ant\u00f3n-Fern\u00e1ndez A, Verwer EE, S\u00e1ez-Calveras N, Meltzer AC, et al. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol. 2017;134:619\u201328.","journal-title":"Acta Neuropathol"},{"key":"4631_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-017-0482-0","volume":"5","author":"M Marqui\u00e9","year":"2017","unstructured":"Marqui\u00e9 M, Verwer EE, Meltzer AC, Kim SJW, Ag\u00fcero C, Gonzalez J, et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson\u2019s case. Acta Neuropathol Commun. 2017;5:75.","journal-title":"Acta Neuropathol Commun"},{"key":"4631_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11307-017-1143-1","volume":"20","author":"AK Hansen","year":"2017","unstructured":"Hansen AK, Brooks DJ, Borghammer P. MAO-B inhibitors do not block in vivo Flortaucipir([18F]-AV-1451) binding. Mol Imaging Biol. 2017;20:356\u201360.","journal-title":"Mol Imaging Biol"},{"key":"4631_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-017-0325-z","volume":"9","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Gillberg P-G, Svedberg M, Stepanov V, Jia Z, Huang J, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9:96.","journal-title":"Alzheimers Res Ther"},{"key":"4631_CR49","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising positron emission tomography (PET) tracer for in vivo quantification of human neurofibrillary tangles (NFTs). J Nucl Med. 2016;57:1599\u2013606.","journal-title":"J Nucl Med"},{"key":"4631_CR50","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1021\/acschemneuro.9b00326","volume":"10","author":"LR Drake","year":"2019","unstructured":"Drake LR, Pham JM, Desmond TJ, Mossine AV, Lee SJ, Kilbourn MR, et al. Identification of AV-1451 as a weak, nonselective inhibitor of monoamine oxidase. ACS Chem Neurosci. 2019;10:3839\u201346.","journal-title":"ACS Chem Neurosci"},{"key":"4631_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12149-019-01344-x","volume":"33","author":"T Tago","year":"2019","unstructured":"Tago T, Toyohara J, Harada R, Furumoto S, Okamura N, Kudo Y, et al. Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. Ann Nucl Med. 2019;33:375\u201382.","journal-title":"Ann Nucl Med"},{"key":"4631_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-018-0556-7","volume":"6","author":"A Ishiki","year":"2018","unstructured":"Ishiki A, Harada R, Kai H, Sato N, Totsune T, Tomita N, et al. Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol Commun. 2018;6:53.","journal-title":"Acta Neuropathol Commun"},{"key":"4631_CR53","first-page":"217","volume":"10","author":"WE Klunk","year":"2018","unstructured":"Klunk WE. Molecular imaging: what is right and what is an illusion? Alzheimer\u2019s Dement Diagn Assess Dis Monit Elsevier. 2018;10:217\u201320.","journal-title":"Alzheimer\u2019s Dement Diagn Assess Dis Monit"},{"key":"4631_CR54","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Sch\u00f6ll M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151\u201362.","journal-title":"JAMA."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04631-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04631-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04631-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T19:08:53Z","timestamp":1608145733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04631-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4631"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04631-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RV has been PI for [<sup>18<\/sup>F]MK6240 phase 1 and [<sup>18<\/sup>F]flutemetamol phase 1 & 2 trials. UZ\/KU Leuven has MTAs wit RV as PI, with Avid Radiopharmaceuticals, Merck, and Tohoku University. UZ\/KU Leuven has current clinical trial agreements with RV as PI with AbbVie, Biogen, EliLilly, Genentech and Roche. RV is a DSMB member of AC Immune phase 2 trial. DRT received consultant honorary from GE-Healthcare (UK), and Covance Laboratories (UK), speaker honorary from Novartis Pharma AG (Switzerland), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). GB collaborated with Janssen (Belgium), Merck (USA), UCB (Belgium), Celgene (USA), Takeda (USA), and Eikonizo (USA). KVL has performed consultancy services and contract research, through KU Leuven, during the past 5\u00a0years for GE Healthcare, Merck Inc., Janssen Pharmaceuticals, UCB, Novartis, Syndesi Therapeutics, Curasen, and Eikonizo. JS, SC, JC, AR, KS and TT have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individuals or their spouses for brain donation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}